Does combining urine sediment examination to renal cell arrest and damage biomarkers improve prediction of progression and mortality of sepsis associated acute kidney injury?

将尿沉渣检查与肾细胞停滞和损伤生物标志物相结合,能否提高对脓毒症相关急性肾损伤进展和死亡率的预测?

阅读:1

Abstract

BACKGROUND: Sepsis associated acute kidney injury (SA-AKI) among hospitalized patients is common with higher morbidity and mortality. There is a need to discover new methods that allow better prediction of its outcomes and prognosis. We aimed to evaluate if combining serial examination of urine sediment to renal cell damage (KIM-1) and arrest (TIMP-2, IGFBP7) biomarkers could improve the prediction of progression and mortality of SA-AKI. METHODS: This prospective study enrolled 96 patients with stage 1 or 2 SA-AKI. Measuring of urinary TIMP-2, IGFBP7 and KIM-1 was done at time of AKI diagnosis and examination of urine sediment was performed by calculating Chawla score (CS) and Perazella score (PS) at days 1, 3 and 7. Main study outcomes included AKI progression to stage 3 and mortality. RESULTS: Ninety-six patients were included in the study. 48% of them progressed to AKI stage 3 and 33.3% died. uTIMP2*IGFBP7 and uKIM-1 showed an area under the curve (AUC) of 0.837 and 0.657 respectively for predicting AKI progression and an AUC of 0.679 and 0.626 respectively for predicting mortality. Combining urine sediment examination at day 3 (P2 and C2) to uTIMP2*IGFBP7, uKIM-1 and both biomarkers significantly improved their prediction ability to an AUC of to 0.977, 0.951 and 0.979 respectively to predict AKI progression, and to an AUC of 0.807, 0.796 and 0.803 respectively to predict mortality. CONCLUSIONS: Combining urine sediment examination with renal cell damage and arrest biomarkers significantly improved their performance of predicting AKI progression and mortality in patients with SA-AKI. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov Identifier: NCT06064487. First registration date: 21/09/2023.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。